The <scp>ARTIST</scp> Post‐Market Study: Evaluating a High G' Hyaluronic Acid ( <scp>HA</scp> ) Injectable for Chin Combined With Midface <scp>HA</scp> Filler Treatments

ABSTRACT Background A novel hyaluronic acid (HA) injectable (Restylane Shaype, HA SHA ) with high strength/firmness and enhanced HA concentration, optimized for lower face shaping has been developed. Aims This prospective, 8‐week, multicenter, post‐market study evaluated three treatment algorithms, i.e., the Shayping Technique, for subjects with multiple aesthetic needs, including HA SHA for chin augmentation alone/in combination with treatments for the lower face and midface with HA DEF (Restylane Defyne) and HA LYF (Restylane Lyft Lidocaine). Patients/Methods Subjects ≥ 18 years were assigned to one of the following treatments: Group 1: HA SHA (chin); Group 2: HA SHA (chin) and HA DEF (marionette line areas laterally to the chin); Group 3: HA SHA (chin), HA DEF (marionette line areas laterally to the chin), and HA LYF (midface and/or nasolabial fold [NLF, piriform fossa] and/or jawline). Assessments included Global Aesthetic Improvement Scale (GAIS), subject and investigator satisfaction, and collection of adverse events (AEs). Results The GAIS responder rate (“improved,” “much improved,” or “very much improved”) was 100% in all groups at Week 8 (primary endpoint) and Week 4 as assessed by the investigator and by subject self‐assessment at Weeks 4 and 8. Overall subject and investigator satisfaction with treatment was high, and the safety profile for all product combinations was favorable, with no unexpected AEs. Conclusions Treatment with HA SHA for chin augmentation alone/in combination with HA DEF and HA LYF for comprehensive lower face and midface lift was safe and effective, with 100% aesthetic improvement at 8 weeks post‐injection. The Shayping Technique provides standardized guidance for practitioners to perform safe injections and achieve optimal aesthetic outcomes.